Filter your results
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
sorted by
|
|
A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensificationSeminars in Oncology, 2017, 44 (1), pp.24 - 33. ⟨10.1053/j.seminoncol.2017.02.007⟩
Journal articles
inserm-01819425v1
|